

CancerPACTtm



Cancer Patients' Alliance for Clinical Trials

Denver Area Adult Cancer Clinical Trials Summer 2011

Solid Tumors

1. Breast	2
2. Central Nervous System	4
3. Gastrointestinal	5
4. Gynecologic	6
5. Head and Neck	8
6. Lung	8
7. Melanoma	11
8. Prostate	11
9. Urologic	12

Hematologic Cancers

1. Leukemia	13
2. Lymphoma	13
3. Myeloma	14

Phase I Studies	16
------------------------------	----

Other	17
--------------------	----

Contact Organizations:

- Colorado Cancer Research Program (CCRP) 303-777-2663
Denver Health (DH) 303-602-6061
- Rocky Mountain Cancer Centers (RMCC) 888-259-7622
- University of Colorado Cancer Center (UCCC) 720-848-0018

CancerPACT is an initiative of the Cancer Patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244

www.CancerPACT.org

Solid Tumors

1. Breast Cancer

1. **2009-APBI Phase III Randomized Study Comparing Intensity Modulated Planning vs. 3-Dimensional Planning for Accelerated Partial Breast Radiotherapy (RMCC)**
2. 40601 Phase III Randomized Trial of Paclitaxel Combined with Trastuzumab, Lapatinib or Both as Neoadjuvant Treatment of HER2-positive Primary Breast Cancer (CRRP, RMCC)
3. **B-39 Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer (CCRP, RMCC, UCCC)**
4. B-41 Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response (CCRP, DH, RMCC, UCCC)
5. **B-43 Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy (CCRP, RMCC)**
6. B-44-I Phase III Multicenter Randomized Trial of Adjuvant Therapy for Patients with Her2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab (RMCC)
7. **B-46-I Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer (CCRP, RMCC)**
8. B-47 Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer (CRRP, RMCC)
9. **EGF108919 Phase III Randomized, Open-Label Study of Taxane-Based Chemotherapy with Lapatinib or Trastuzumab as First Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer (DH)**
10. S0500 Phase III Randomized Trial to Test the Strategy of Changing Therapy vs. Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow up Assessment (UCCC)
11. **SWOG 0221 Phase III Trial of Continuous Schedule AC + G vs. Q 2wk Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer (DH, UCCC)**

Contact Organizations:

[Colorado Cancer Research Program \(CRRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

12. **40502 CALGB A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumen Bound Nab-Paclitaxel or Ixabepilone with or without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer (CCRP)**
13. USON 08217 Phase III Randomized Double-Blind Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First Line Therapy in Women with HER2-Positive Locally Advanced or Metastatic Breast Cancer (RMCC)
14. **USON 08223 Phase III Randomized Double-Blind, Placebo-Controlled Multicenter Trial of Daily Everolimus in Combination with Trastuzumab and Vinorelbine, in Pretreated Women with HER2/neu Over-Expressing Locally Advanced or Metastatic Breast Cancer (RMCC)**
15. USON 09008 Phase III Multi-Center Open-Label Randomized Trial of Gemcitabine/Carboplatin, with or without BSI-201, in Patients with ER, PR, and HER2-Negative Metastatic Breast Cancer (RMCC)
16. **USON 09054 Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Denosumab as Adjuvant Treatment for Women with Early Stage Breast Cancer at High Risk of Recurrence (D-CARE) (RMCC)**
17. 4053 CALGB Endocrine Therapy With or Without anti-VEGF Therapy: A Randomized Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) For Women with hormone Receptor-Positive Advanced Breast Cancer (CCRP)
18. **N0937 Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer (CCRP)**
19. 40603 Randomized Phase II 2 X 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer (CCRP, RMCC)
20. **E3108 Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen (CRRP)**
21. FB-7 Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel and Neratinib or Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer (CCRP, RMCC)
22. **N0733 Phase II Randomized Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or Taxane (CCRP, RMCC)**
23. USON 06185 Phase II Randomized Trial of Letrozole with or without Dasatinib as First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Post-Menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic (RMCC)
24. **USON 07142 Phase II, Open-Label Study of EZN-2208 (PEG-SN38) in Patients with Previously Treated Metastatic Breast Cancer (RMCC)**
25. USON 08007 Phase II Trial of Ixabepilone Plus Carboplatin in Patients with Metastatic Breast Cancer (RMCC)
26. **Phase II Randomized Trial using Differential Gene Regulation During Neoadjuvant Therapy Trial of Epirubicin/Cyclophosphamide (EC) Docetaxel/Capecitabine (DX) Regimens in Patients with Large ER-Positive and ER-Negative Breast Cancer (UCCC)**

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

27. Phase II Randomized Pilot Study to Identify Molecular Predictors for Hormone Responsiveness. Preoperative Hormone Therapy for Postmenopausal Women with ER+ or PR+ Clinical Stage T2-4 Tumors: Exemestane with or without Tamoxifen (UCCC)
28. **CZOL446E2352 A Prospective Randomized Double-Blind, Stratified, Multi-Center Two-Arm Trial of the Continued Efficacy and Safety of Zometa (Every 4 Weeks vs. Every 12 Weeks) in Patients with Documented Bone Metastases from Breast Cancer (DH)**
29. **I-SPY2: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2 (UCCC)**
30. TDM4884g Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (RMCC)
31. **USON 09185 Open-Label, Expanded Access Protocol of Iniparib in Combination with emcitabine/Carboplatin in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer (RMCC)**
32. USON 10002 A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalatuzamab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients (RMCC)
33. **A Translational Study of the Interactions between Prior Pregnancy and the Biologic Subtype of Breast Cancer in Defining the Cancer: Host Immunologic Interaction (UCCC)**
34. Lapatinib in Endocrine-Resistant Metastatic Breast Cancer (UCCC)
35. **Reducing Breast Cancer Recurrence with Weight Loss: A Vanguard Trial Restoration of microRNAs: A Form of Differentiation Therapy for Treatment of Aggressive Breast Cancers (UCCC)**
36. Window of Opportunity Study Targeting the Inflammatory Milieu of Pregnancy Associated Breast Cancer (UCCC)

2. Central Nervous System Tumors

1. **NCCTG N0574/N0547 Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases (CCRP, UCCC)**
2. E3F05 Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas (CRRP, RMCC)
3. **N0577 NCCTG Phase III Intergroup Study of Radiotherapy versus Temozolomide alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma (CCRP)**
4. **RTOG 0539 Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate and High-Risk Meningiomas (UCCC)**
5. N057K Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma (CCRP)

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

3. Gastrointestinal Cancers

A. Colorectal Cancer

1. **80702 Phase III Trial of Six vs. Twelve Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer (CCRP, RMCC)**
2. C80405 Phase III Trial of Irinotecan, 5-FU, Leucovorin or OXaliplatin, 5-FU, Leucovorin with Bevacizumab or Cetuximab or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum (CCRP, DH, UCCC)
3. **Perifosine 343 Phase III Randomized Double-Blind Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine vs. Placebo Plus Capecitabine in Patients with Refractory Advanced Colorectal Cancer (RMCC)**
4. USON 10101 Phase III Randomized, Double-Blind, Multicenter Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucicromab or Placebo in Patients with Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine (RMCC)
5. **N0949 NCCTG Randomized Phase III Trial of mFOLFOX7 or XELOX plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer (CCRP)**
6. E4203 Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer (CCRP, RMCC)
7. **USON 08113 Phase II Randomized, Multicenter Study to Compare the Efficacy of Panitumumab in Combination with mFOLFOX6 to the Efficacy of Bevacizumab in Combination with mFOLFOX6 in Patients with Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer (RMCC)**
8. Duke XELOX-A-D 00010354 Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients with Advanced Solid Tumors with Expanded Cohort of Patients with Previously Untreated Metastatic Colorectal Cancer (RMCC)
9. **Phase I/IB Study of OSI-906 and Irinotecan in Patients with Advanced Cancer with Expanded Cohorts of Patients with Colorectal Cancer Stratified by the OSI-906 Integrated Classifier (UCCC)**
10. P-5 Statin Polyp Prevention Trial in Patients with Resected Colon Cancer (CCRP, RMCC)

B. Esophageal Cancer

1. **0436 Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin and Radiation for Patients with Esophageal Cancer Who are Treated without Surgery (CCRP, RMCC)**
2. 1010 RTOG A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma (CCRP)

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

3. **E2208 Randomized Phase II Study of Paclitaxel, Carboplatin, Bevacizumab with or without Cixutumumab (IMC-A12) as Second Line Treatment for Patients with Metastatic Esophageal or GE Junction Cancer (CCRP)**
4. **E1308 Phase II Trial of Induction Chemotherapy Followed by Cetuximab (Erbix) with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx (CCRP RMCC)**

C. Gastric Cancer

1. **USON 08055 Phase III Randomized Multi-Center Study to Evaluate the Efficacy and Safety of Nilotinib vs. Imatinib in Adult Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) (RMCC, UCCC)**

D. Pancreatic Cancer

1. **0848 Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (CCRP)**
2. **Phase III Randomized Study of Weekly ABI-007 Plus Gemcitabine vs. Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas (UCCC)**
3. **CO-101-003 Phase II Open-Label, Multicenter Study to Evaluate the Antitumor Efficacy of CO-1.01 for Infusion as Second-Line Therapy for Gemcitabine-Refractory Patients with Stage IV Pancreatic Adenocarcinoma and No Tumor hENT1 Expression (RMCC)**
4. **MC0547 Phase II Trial of AZD0530 in Previously Treated Metastatic Pancreas Cancer (UCCC)**
5. **USON 10099 Phase II Randomized Cross-Over Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination with Gemcitabine Compared with Gemcitabine Alone in Previously Untreated Patients with Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma (RMCC)**

4. Gynecologic Cancers

A. Ovarian / Peritoneal Cancer

1. **GOG-0212 Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 vs. No Treatment until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve A Complete Clinical Response To Primary Platinum/Taxane Chemotherapy (CCRP, RMCC, UCCC)**

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

2. GOG-0213 Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube and Peritoneal Primary Cancer (CCRP, RMCC, UCCC)
3. **GOG-0252 Phase III Clinical Trial of Bevacizumab with IV vs. IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma (UCCC)**
4. MORAb-003-004 Phase III Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-Sensitive Ovarian Cancer in First Relapse (DH)
5. **GOG-0254 Phase II Evaluation of SU11248 (Sunitinib Malate) (IND# 74019, NSC# 736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma (UCCC)**
6. GOG-0268 Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864, IND# 61010) in Combination with Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary (UCCC)
7. **GOG-0256 Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer (UCCC)**
8. **GOG 8199 Prospective Study of Risk-Reducing Salpingo-Oophorectomy (RRSO) and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer: Extended Follow-Up of Select GOG-0199 Study Participants (UCCC)**
9. GOG-0259 Nurse-Delivered Write Symptoms vs. Self-Directed Write Symptoms vs. Care as Usual for Optimal Symptom Management for Women with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (UCCC)

B. Uterine / Cervical Cancer

1. **GOG-0240 Randomized Phase III Trial of Cisplatin Plus Paclitaxel with and without NCI-Supplied Bevacizumab (NSC #704865, IND #7921) vs. the Non-Platinum Doublet, Topotecan Plus Paclitaxel, with and without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix (CCRP, RMCC, UCCC)**
2. GOG-0249 Phase III Trial of Pelvic Radiation Therapy vs. Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma (CCRP, UCCC)
3. **GOG-0250 Phase III Randomized Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC#613327) Plus G-CSF with Bevacizumab (NSC #704865, IND #7921) vs. Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus (CCRP, RMCC, UCCC)**
4. GOG 0258 Phase III Randomized Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma (UCCC)

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

5. **GOG-0261 Randomized Phase III Trial of Paclitaxel plus Carboplatin vs. Ifosfamide plus Paclitaxel in Chemotherapy- Naive Patients with Newly Diagnosed Stage I-IV or Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus (UCCC)**
6. GOG-0086P Phase II Three Arm Randomized Study of Paclitaxel/Carboplatin/Bevacizumab (NSC#704865, IND#7921), and Ixabepilone (NSC#710428, IND# 59699) /Carboplatin/BEvacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer (UCCC)
7. **GOG-0130F Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus (UCCC)**
8. Phase II Study to Determine the Response to Second Curettage as Initial Mangement for Persistent Low Risk, Non Metastatic Getational Trophoblastic Neoplasia (UCCC)
9. **GOG 0210 A Molecular Staging Study of Endometrial Carcinoma (UCCC)**
10. GOG 0238 Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic only Recurrence of Carcinoma of the Uterine Corpus (UCCC)

5. Head & Neck Cancer

1. **0920 Phase III Study of Radiation Therapy (IMRT) +/- Cetuximab (C225) for Intermediate Risk Resected Head and Neck Cancer (CCRP, DH, RMCC, UCCC)**
2. E1305 Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer (CCRP, RMCC)
3. **RTOG 0619 Phase II Randomized Trial of Chemoradiotherapy vs. Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck (DH)**
4. Phase II Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination with Cetuximab in Second-Line Cetuximab-Na'Ve Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) (UCCC)
5. **RTOG 0514 Establishment of Head and Neck Cancer Tissue/Specimen Repository (DH)**

6. Lung

1. **CALGB 30610, RTOG 0538 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide (CCRP, RMCC, UCCC)**
2. E1505 Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> 4 cm) – IIIA Non-Small Cell Lung Cancer (NSCLC) (CCRP, DH, RMCC, UCCC)

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

3. **E5508 Phase III Randomized Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC (CCRP, RMCC)**
4. RTOG 0538 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide (UCCC)
5. **RTOG 0617 (NCCTG N0628, CALGB 30609) Phase III Randomized Comparison of Standard-Dose (60Gy) vs. High Dose (74Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/ Paclitaxel ± Cetuximab in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer (CCRP, RMCC, UCCC)**
6. S0819 Phase III Randomized Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/ Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced NSCLC (CCRP, DH, RMCC, UCCC)
7. **START - Stimulating Targeted Antigenic Responses to NSCLC. Phase III Multi-Center Randomized, Double-Blind Placebo-Controlled Study of the Cancer Vaccine Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Non-Small Cell Lung Cancer (NSCLC) Subjects with Unresectable Stage III Disease (UCCC)**
8. **USON 10061 Phase III Randomized, Double-Blind Study of Docetaxel and Ramucirumab vs. Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum- Based Therapy (RMCC)**
9. Phase III Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy of RecMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive NSCLC (UCCC)
10. **Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients with Non-Small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens (UCCC)**
11. Registration Phase III Study of Lucanix (Belagenpumatucel-L) in Advanced Non-Small Cell Lung Cancer: An International Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of Lucanix Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-Line, Platinum-Based Combination Chemotherapy (UCCC)
12. **CS7017 Phase II Study of CS-7017 and Erlotinib in Subjects with Advanced NSCLC Who Failed First Line Therapy (DH, UCCC)**
13. E1508 Phase II Randomized Study of Cisplatin and Etoposide in Combination with Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMCA12 for Patients with Extensive Stage Small Cell Lung Cancer (CCRP, RMCC)
14. **E3508 A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab with or without IMC-A12 in Patients with Advanced Non-Squamous, Non-Small Cell Lung Cancer (CCRP)**
15. **S0709 Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with Performance Status 2 (PS-2) Selected by Serum Proteomics (UCCC)**
16. S0720 Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage 1 Non-Small Cell Lung Cancer (NSCLC) (UCCC)

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

17. **S0722 Phase II Trial of MTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM) (UCCC)**
18. S0802 Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (UCCC)
19. **SWOG S0635 Phase II Trial of the Combination of OSI-774 and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features (UCCC)**
20. USON 09078 Phase II Study to Evaluate LY2603618 in Combination with Pemetrexed in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (RMCC)
21. **Phase II Open Label, Multicenter, Randomized Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-Based Chemotherapy vs. Platinum-Based Chemotherapy Alone as First-Line Treatment of Patients with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) (UCCC)**
22. Phase II Randomized Chemoprevention Study of Pioglitazone vs. Placebo in Patients at High Risk for Lung Cancer (UCCC)
23. **Phase II Randomized Study of Imetelstat as Maintenance Therapy after Initial Induction Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) (UCCC)**
24. Phase II Trial of Erlotinib (Tarceva) in Combination with Stereotactic Body Radiation Therapy (SBRT) for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (UCCC)
25. **RTOG 0813 Seamless Phase I/II Study Of Stereotactic Lung Radiotherapy (SBRT) For Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) In Medically Inoperable Patients (UCCC)**
26. Phase I Open-Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Combined Oral C-Met/Alk Inhibitor (Pf-02341066) and Pan-Her Inhibitor (Pf-00299804) in Patients with Advanced Non-Small Cell Lung Cancer (UCCC)
27. **S0424 Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men (DH)**
28. SPORE 4: Analysis of Intermediate Endpoint Biomarkers in the Respiratory Epithelium of Smokers Compared to Non-Smoking Controls (UCCC)
29. **SPORE 24: Biomarkers and Dysplastic Respiratory Epithelium (Version B) (UCCC)**
30. USON 08035 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects with Advanced Stage Non-small Cell Lung Cancer Receiving Multi-Cycle Chemotherapy (RMCC)
31. **An Exploratory Analysis of Exhaled Nitric Oxide Concentration in Patients with Lung Cancer Receiving Thoracic Radiotherapy (UCCC)**
32. Biomarkers for Diagnosis of Lung Nodules (UCCC)
33. **Feasibility Study Investigating Translational Science in Chemotherapy-Naive Patients with Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) Treated with the EGFR-TKI, Erlotinib (UCCC)**
34. Lung Cancer Mutation Consortium Protocol (UCCC)
35. **Lung Cancer Specimen Repository (DH)**
36. Lung Cancer Tissue Bank Protocol (UCCC)
37. **Pilot Study Exploring the Clinical Significance of Basal Apoptotic Rate as a Predictive Marker of Treatment Response and of Treatment-Related Toxicities in Patients with Epithelial Lung Tumors (UCCC)**

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

7. Melanoma

1. **The TEAM Trial (Tasigna Efficacy In Advanced Melanoma): Phase III Randomized Open Label, Multi-Center, Two-Arm Study to Compare the Efficacy of Tasigna vs. Dacarbazine (DTIC) in the Treatment of Patients with Metastatic and/or Inoperable Melanoma Harboring a C-Kit Mutation (UCCC)**
2. E1608 Phase II Trial of GM-CSF Protein plus Ipilimumab in Patients with Advanced Melanoma (CCRP, RMCC)
3. **N0879 Phase II Randomized Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma (CCRP, RMCC)**
4. USON 10052 Phase II Open-Label, 2-Cohort, Multicenter Study of E7080 in Previously Treated Subjects with Unresectable Stage III or Stage IV Melanoma (RMCC, UCCC)
5. **Phase II Study of Marqibo in Patients with Metastatic Uveal Melanoma (UCCC)**
6. Phase I/II Open-Label, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma (UCCC)
7. **Gene Expression in Peripheral Blood to Predict Recurrence of Malignant Melanoma (UCCC)**
8. Phase IB, Open Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of RO5185426 in Combination with GDC-0973 when Administered in Patients with BRAFV600E-Positive Metastatic Melanoma who have Progressed after Treatment with RO5185426 (UCCC)

8. Prostate Cancer

1. **0534 Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy (CCRP, RMCC, UCCC)**
2. C90203 PUNCH Randomized Phase III Study of Neoadjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs. Immediate Radical Prostatectomy in Patients with High Risk Clinically Localized Prostate Cancer (DH, UCCC)
3. **PR11 Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favorable Risk Prostate Cancer (START) (UCCC)**
4. RTOG 0815 Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer (UCCC)
5. **USON 09073 Phase III Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone with or without Lenalidomide in Subjects with Castrate-Resistant Prostate Cancer (RMCC)**

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

6. USON 10164 Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (RMCC)
7. **E2809 Phase II Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy (CCRP, RMCC)**
8. RTOG 0526 Phase II Prospective Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy (UCCC)
9. **Phase I & II Study of Stereotactic Body Radiation Therapy (SBRT) for Low and Intermediate Risk Prostate Cancer (UCCC)**
10. E3805, CHARTED: ChemoHormonal Therapy vs. Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (UCCC)
11. **Study to Define Protein Signatures for Prostate Cancer Progression (UCCC)**

9. Urologic Cancers (other)

A. Bladder

1. **CALGB-90601 Phase III Randomized Double-Blinded Study Comparing Gemcitabine, Cisplatin, and Bevacizumab (IND #7921, NSC #704865) to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma (CCRP, RMCC, UCCC)**
2. S0337 Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine vs. Saline in Patients with Newly Diagnosed or Occasional Recurring Grade I/II Superficial Bladder Cancer (UCCC)
3. **USON 09187 Phase IB/II Open-Label, Multicenter, Randomized Study of Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin vs. Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer (RMCC)**

B. Kidney Cancer

1. **Phase II Study to Determine the Effect of Two Different Doses of AVE0005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma (CCRP, RMCC)**

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

Hematologic Cancers

1. Leukemia

1. **E2905 Phase III Randomized Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low or Intermediate-1 Risk MDS and Symptomatic Anemia (CCRP, RMCC)**
2. OMB110911 Phase III Open Label Randomized Trial of Ofatumumab Added to Chlorambucil vs. Chlorambucil Monotherapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia (DH)
3. **CALGB 10403 Phase II Intergroup Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL) (CCRP, RMCC)**
4. E2903 Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treat Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia (CCRP, RMCC)
5. **RC0783 Phase II Randomized Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL) (CCRP, RMCC)**
6. E3903 Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders (CCRP)
7. **USON 10034 The Chronic Lymphocytic Leukemia Disease Registry, CONNECT CLL (RMCC)**
8. Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (UCCC)
9. **Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen (UCCC)**

2. Lymphoma

1. **Phase IV Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 Mg/Kg) Compared to a Fixed Dose (20mg) of Plerixafor Injection in Combination with G-CSF to Mobilize and Collect Greater Than or Equal to 5 Million Cd34+Cells/Kg in Less Than or Equal to Four Days and to Evaluate the Difference in Total Sytemic Exposure in Patients with Non-Hodgkin's Lymphoma Weighing Less than or Equal to 70kg (UCCC)**
2. CALGB 50303 Phase III Randomized Study of R-CHOP vs. Dose Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas (CCRP, RMCC)

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

3. **CC-5013-CLL-002 Phase III Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid) as Maintenance Therapy for Patients with B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy [The CONTINUUM Trial] (UCCC)**
4. CRAD001N2301 Phase III Randomized Double-Blind Placebo-Controlled, Multi-Center Study of RAD001 Maintenance Therapy in Elderly, High Risk Patients with Advanced Diffuse Large B-Cell Lymphoma (DLBCL) to Compare the Safety and Efficacy of RAD001 vs. Matching Placebo after Patients have Achieved Complete or Partial Response with First-Line Rituximab-Chemotherapy (DH, RMCC)
5. **OMB113676 Phase III Randomized, Open Label Study of Single Agent Ofatumumab vs. Single Agent Rituximab in Follicular Lymphoma Relapsed after Rituximab-Containing Therapy (DH)**
6. 09-214 Phase II Study of Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia (RMCC)
7. **E2408 Phase II 3-Arm Randomized Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma (CCRP)**
8. S0816 Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Early Interim FDG-PET Imaging (CCRP, RMCC)
9. **USON 09064 Phase II Open-Label, Randomized Study to Assess the Effectiveness of RCHOP with or without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma (RMCC)**
10. 16201 Phase IB/II Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Bendamustine vs. Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (RMCC)
11. **C16002 Phase I Open-Label Dose-Escalation Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Lymphoma (RMCC)**
12. Phase I Trial of PF-03084014 in Patients with Advanced Solid Tumor Malignancy and T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (UCCC)
13. **USON 07152 Open-Label Randomized Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) (RMCC)**

3. Myeloma

1. **10603 Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND # 101261)**

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

- or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML) (CCRP, RMCC)**
2. E1A06 Phase III Intergroup Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) vs. Melphalan, Prednisone and Lenalidomide (Revlimid) (MPR) in Newly Diagnosed Multiple Myeloma Patients Who are not Candidates for High-Dose Therapy (CCRP, RMCC)
 3. **E3A06 Phase III Randomized Trial of Lenalidomide vs. Observation alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (CCRP, RMCC)**
 4. S0777 Phase III Randomized Trial of CC-5-13 (Lenalidomide, NSD703813) and Low Dose Dexamethasone (LLD) vs. Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (CCRP, DH, RMCC, UCCC)
 5. **USON 08209 Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib (RMCC)**
 6. E2A08 Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients with Multiple Myeloma Relapsing within 12 Months of Autologous Stem Cell Transplant (CCRP, RMCC)
 7. **Phase II Prospective Study for Therapy with Bortezomib + Lenalidomide + Dexamethasone with Lenalidomide + Dexamethasone as Post Transplant Consolidation and Maintenance for Patients with Symptomatic Multiple Myeloma Following Autologous Transplantation (UCCC)**
 8. Phase II Study of Induction Therapy with Bortezomib + Lenalidomide + Dexamethasone + Doxorubicin (UCCC)
 9. **CLBH589BUS15T Phase I/II Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM) (RMCC)**
 10. 09-0889 FHCRC: Multi-Center Study of Conditioning with Treosulfan, Fludarabine and Escalating Doses of TBI For Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (UCCC)
 11. **08-0817 Pilot Study of Infusional Melphalan + Bortezomib for Myeloablative Therapy Prior to Autologous Transplant for Patients with Multiple Myeloma (UCCC)**
 12. CSTI571A2402 A Worldwide, Observational Registry Collecting Longitudinal Data on the Management of Chronic Myelogenous Leukemia (CML) Patients (The WORLD CML Registry) in Routine Practice (DH)
 13. **USON 09141 The Multiple Myeloma Disease Registry - Registry Protocol (CONNECT MM) (RMCC)**
 14. USON 09152 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Deferasiroz in Patients with Myelodysplastic Syndromes (Low/Int-1 Risk) and Transfusional Iron Overload (TELESTO) (RMCC)
 15. **USON 10128 Multi-Center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients with Low Imatinib trough Plasma Concentrations (RMCC)**
 16. USON 10137 Exploratory Trial to Assess the Improvement of Chronic Low-Grade Non-Hematologic Adverse Events Experienced by Patients with Philadelphia Chromosome Positive (Ph+)

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated with Imatinib when Switched to Nilotinib Treatment (RMCC)

17. Pilot Study of Infusional Melphalan + Bortezomib for Myeloablative Therapy Prior to Autologous Transplant for Multiple Myeloma and Related Disorders (UCCC)

Phase I Studies

1. **ARRAY-380-101 Phase I Open-label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ARRY-380 Given on a Daily Oral Regimen in Subjects with Advanced Cancer (UCCC)**
2. S0711 Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517;IND-73969) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction (UCCC)
3. **USON 05033 Phase I Open Label Multicenter Dose-Escalation Study to Determine the Maximum Tolerated Dose (MTD), Dose Limiting Toxicity (DLT), Safety and Pharmacokinetics of CGC-11047 when used in Individual Combinations with 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Fluorouracil or 7) Sunitinib in Patients with Advanced Solid Tumors or Lymphoma (RMCC)**
4. USON 08008 Phase IB Multicenter Dose-Escalation Study of LY573636 Sodium in Combination with 1) Gemcitabine HCl or 2) Docetaxel or 3) Temozolomide or 4) Cisplatin in Patients with Advanced Solid Tumors (RMCC)
5. **USON 08031 Phase I Multicenter Open-Label Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of NKTR-102 (NKT-10002; PEG-Irinotecan) in Patients with Refractory Solid Tumors (RMCC)**
6. USON 10190 Phase I and Pharmacologic Study of MM-111 in Combination with Multiple Treatment Regimens in Patients with Advanced HER2 Positive Solid Tumors (RMCC)
7. Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients with Advanced or Metastatic Solid Tumors (UCCC)
8. **Phase I Dose Escalation Study of the Safety and Pharmacokinetics of IPI-493 Orally Administered to Patients with Advanced Solid Tumors or Hematologic Malignancies (UCCC)**
9. Phase I Multicenter, Open-Label, Dose Escalation, Study of TAK-441, an Oral Hedgehog Signaling Pathway Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies (RMCC, UCCC)
10. **Phase I Multicenter Open-Label Dose Escalation Trial of PDL192 in Subjects with Advanced Solid Tumors (UCCC)**
11. Phase I Multicenter Open Label Study of Single Agent R7112 Administered Orally in Patients with Advanced Malignancies - Except all Forms of Leukemia (UCCC)
12. **Phase I Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 3 Weeks in Patients with Advanced Solid Malignancies (UCCC)**
13. Phase I Open Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Single Agent PF-03758309, an Oral PAK4 Inhibitor, in Patients with Advanced Solid Tumors (UCCC)

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)

[Denver Health \(DH\) 303-602-6061](#)

[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)

[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244

www.CancerPACT.org

14. **Phase I Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEHD7945A Administered Intravenously to Patients with Locally Advanced or Metastatic Epithelial Tumors (UCCC)**
15. Phase I Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MINT1526A Administered Intravenously to Patients with Locally Advanced or Metastatic Epithelial Tumors (UCCC)
16. **Phase I Open-Label, Multi-Center, Dose-Escalation Study of Oral BGJ298, a Pan FGFR Kinase Inhibitor, in Adult Patients with Advanced Solid Malignancies (UCCC)**
17. Phase I Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 Administered as Daily Oral Monotherapy or in Combination with Docetaxel in Patients with Advanced Solid Malignancies (UCCC)
18. **Phase I Open Label Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAYá73-4506 in Patients with Advanced Malignancies (UCCC)**
19. Phase I Safety and Tolerability Study of Vorinostat in Combination with Sorafenib in Patients with Advanced Solid Tumors with Exploration of Two Tumor Type Specific Expanded Cohorts at the Recommended Phase II Dose (Renal Cell Carcinoma and Non Small Cell Lung Carcinoma) (UCCC)
20. **Phase I Safety Pharmacokinetic and Pharmacodynamic Study of PF-02341066 a C-Met/HGFR Selective Tyrosine Kinase Inhibitor Administered Orally to Patients with Advanced Cancer (UCCC)**
21. Phase I Study of IPI-926 in Patients with Advanced and/or Metastatic Solid Tumor Malignancies (UCCC)
22. **Phase I Study to Assess the Tolerability, Pharmacokinetics and Clinical Activity of ON 01910.Na Concentrate Administered Orally as Escalating Multiple Doses Twice a Day up to 21 Days of a 21-Day Cycle in Patients with Advanced Cancer (UCCC)**
23. Phase I Trial of Arsenic Trioxide in the Treatment of Infiltrating Gliomas of Childhood (UCCC)
24. **Phase I Trial of Oral PX-866 (a PI-3K Inhibitor) in Patients with Advanced Solid Tumors (UCCC)**
25. Phase IB Open Label Dose Escalation Study of the Safety and Pharmacology of GDC-0941 in Combination with Erlotinib in Patients with Advanced Solid Tumors (UCCC)

Other

1. **CALGB 70604 Phase III Randomized Study of Standard Dosing vs. Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer (CCRP, RMCC)**
2. E1208 Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion (DH, UCCC)
3. **N07C2 Phase III Randomized Double-Blind Placebo-Controlled Study of the Use of Wisconsin Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue (CCRP, RMCC)**

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

4. N08CA Phase III Randomized, Double-Blind Placebo Controlled Study of the Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy (CCRP, RMCC)
5. **N08CB Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (CCRP, RMCC)**
6. RTOG 0433 Phase III International Randomized Trial of Single vs. Multiple Fractions for Re-Irradiation of Painful Bone Metastases (UCCC)
7. **S0518 Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha vs. Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients (UCCC)**
8. USON 09129 Phase III Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban vs. (LMW) Heparin/Warfarin in Subjects with Symptomatic Deep-Vein Thrombosis and/or Pulmonary Embolism (RMCC)
9. **USON 09182 Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients with Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment (RMCC)**
10. Multi-Center Open Label Single Arm Study of Yondelis (Trabectedin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma Who have Relapsed or are Refractory to Standard of Care Treatment. Phase III ET743-SAR-3002 (UCCC)
11. **Phase III Multi-Center, International, Randomized, Double-Blind, Placebo-Controlled Study of Doxorubicin Plus Palofosfamide-Tris vs. Doxorubicin Plus Placebo in Patients with Front-Line Metastatic Soft-Tissue Sarcoma: The PICASSO III Study (UCCC)**
12. Phase III Randomized, Double-Blind, Placebo-Controlled Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma (UCCC)
13. **USON 09115 Phase II Open-Label Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination with Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, or nab-Paclitaxel in Subjects with Advanced Solid Tumors (RMCC)**
14. Phase II Randomized, Multicenter, Double-Blind Trial of a GM2, GD2 Lactone, and GD3 Lactone with the Immunological Adjuvant OPT-821 vs. OPT-821 Alone in Metastatic Sarcoma Patients Who are Rendered Disease Free (UCCC)
15. Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer (UCCC)
16. **Phase IB/II Randomized Phase II Study Evaluating the Efficacy of Doxorubicin with or without a Human Anti-PDGFR α Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma (UCCC)**
17. N0392 Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials (CCRP)
18. **N0745 Phase I/II Randomized Study of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced of Metastatic Hepatocellular Carcinoma (CCRP)**
19. 09-0867 Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen (UCCC)

Contact Organizations:

[Colorado Cancer Research Program \(CCRP\) 303-777-2663](#)
[Denver Health \(DH\) 303-602-6061](#)
[Rocky Mountain Cancer Centers \(RMCC\) 888-259-7622](#)
[University of Colorado Cancer Center \(UCCC\) 720-848-0018](#)

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org

20. **09-1115 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control CMV Infection in R+ Hematopoietic Stem Cell Transplant Recipients (UCCC)**
21. Carter 2005-01 Prospective Investigation of Definitive Targeted Therapy for Solid Malignancies with Oligometastases (RMCC)
22. **GIDEON. Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (UCCC)**
23. GOG 0136 Acquisition of Human Gynecologic Specimens and Serum to be used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer (UCCC)
24. MTP-OS-403 Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine (L-MTP-PE): Compassionate Access for High-risk Osteosarcoma (RMCC)
25. **N08C1 Paclitaxel-Associated Acute Pain Syndrome Natural History Study (CCRP, RMCC)**
26. N09C6 Randomized Double-Blind Study of Doxepin Rinse vs. Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy with or without Chemotherapy (CCRP)
27. **S0702 A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment (CCRP, RMCC)**
28. USON 09101 Randomized Discontinuation Study of SL184 in Subjects with Advanced Solid Tumors (RMCC)
29. **Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family Kinases using Erlotinib and Dasatinib in Head and Neck and Lung Cancers (UCCC)**
30. Pilot Study of Cognitive Impairment in Cancer Patients Following Chemotherapy (UCCC)
31. **Rollover Protocol for Patients who Received CP-675,206 in Other Protocols (UCCC)**
32. Study of Continuous Infusion of Melphalan for Induction and Myeloablative Therapy for Autologous Stem Cell Transplant for Patients with Light Chain Amyloidosis (UCCC)
33. **Two Stage Multi Center Open Label Study of Mapatumumab ([HGS1012] A Fully Human Monoclonal Antibody to Trail-r1) in Combination with Sorafenib as First Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (UCCC)**

Contact Organizations:

Colorado Cancer Research Program (CCRP) 303-777-2663
 Denver Health (DH) 303-602-6061
 Rocky Mountain Cancer Centers (RMCC) 888-259-7622
 University of Colorado Cancer Center (UCCC) 720-848-0018

CancerPACT is an initiative of the Cancer patients Alliance, Colorado Cancer Research Program, Colorado Cancer Coalition, Colorado Department of Public Health and Environment, Colorado Foundation for Public Health and the Environment, Denver Health, La Clinica Tepeyac, Latino American Health Network (Colorado Springs), and University of Colorado Cancer Center.

Call (toll free) 1-888-729-0244
www.CancerPACT.org